lif_dk Arkiv - NHTA https://nhta.com/tag/lif_dk/ Tue, 14 Apr 2026 08:43:00 +0000 en-US hourly 1 https://wordpress.org/?v=7.1 https://nhta.com/wp-content/uploads/2025/06/favicon-150x150.png lif_dk Arkiv - NHTA https://nhta.com/tag/lif_dk/ 32 32 The Danish Association of the Pharmaceutical Industry (LIF) warns: MFN could intensify pressure on Denmark’s drug reimbursement system. https://nhta.com/the-danish-association-of-the-pharmaceutical-industry-lif-warns-mfn-could-intensify-pressure-on-denmarks-drug-reimbursement-system/ Tue, 14 Apr 2026 08:43:00 +0000 https://nhta.com/the-danish-association-of-the-pharmaceutical-industry-lif-warns-mfn-could-intensify-pressure-on-denmarks-drug-reimbursement-system/ A US “most-favored nation” (MFN) pricing model could intensify pressure on Denmark’s drug reimbursement system. In a debate article, LIF describes MFN as a plan for the US to purchase medicines at the lowest prices among selected countries, including Denmark-meaning a low Danish price could have global consequences for companies. What Lif highlights Denmark’s reimbursement...

Indlægget The Danish Association of the Pharmaceutical Industry (LIF) warns: MFN could intensify pressure on Denmark’s drug reimbursement system. blev først udgivet på NHTA.

]]> A US “most-favored nation” (MFN) pricing model could intensify pressure on Denmark’s drug reimbursement system.

In a debate article, LIF describes MFN as a plan for the US to purchase medicines at the lowest prices among selected countries, including Denmark-meaning a low Danish price could have global consequences for companies.

What Lif highlights

  • Denmark’s reimbursement process is increasingly rejecting retail pharmacy medicines based mainly on price; Lif notes that all three reimbursement rejections in 2025 were due to the price.

  • MFN could add another barrier to access for new retail pharmacy medicines, with risks of fewer launches, more price-driven rejections, and a narrower product range.

  • LIF argues reimbursement assessments focus too narrowly on list price and do not systematically account for broader effects such as fewer hospitalisations, reduced sick leave, better disease control, higher quality of life, and lower use of other health services.

What LIF calls for is modernising the reimbursement system, securing faster access “from day one,” and keeping/expanding flexible confidential agreements so Danish prices are not directly used in international MFN regimes.

Read more at https://www.lif.dk/tilskudssystemet-er-allerede-presset-og-most-favored-nation-forvaerrer-udviklingen/

Indlægget The Danish Association of the Pharmaceutical Industry (LIF) warns: MFN could intensify pressure on Denmark’s drug reimbursement system. blev først udgivet på NHTA.

]]>